Voices
Andrea Necchi: Pembro Monotherapy Remains the Unsolved Comparator Arm of Perioperative Trials
Andrea Necchi/LinkedIn

Andrea Necchi: Pembro Monotherapy Remains the Unsolved Comparator Arm of Perioperative Trials

Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on X:

“PURE01 trial continues to strike. Updated 5y OS from PURE01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with MIBC (N=155):

  • 5y EFS 68%
  • 5y OS 77%
  • claudin low subtype tumors confirming outstanding benefit

Pembro monotherapy remains the unsolved comparator arm of perioperative trials.”

Title: Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer

Authors: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, Joep J. de Jong, James A. Proudfoot, Brigida A. Maiorano, Antonio Cigliola, Chiara Mercinelli, Elai Davicione, Marco Moschini, Giovanni Tremolada, Simone Rota, Giorgio Brembilla, Maurizio Colecchia, Francesco De Cobelli, Francesco Montorsi, Andrea Necchi

Read the Full Article.

Andrea Necchi: Pembro Monotherapy Remains the Unsolved Comparator Arm of Perioperative Trials

More posts from Andrea Necchi.

Andrea Necchi Antonio Cigliola Brigida A. Maiorano cancer Chiara Mercinelli Elai Davicione Francesco De Cobelli Francesco Montorsi Giorgio Brembilla Giovanni Tremolada Giuseppe Basile James A. Proudfoot Joep J. de Jong Marco Moschini Maurizio Colecchia OncoDaily Oncology Patrizia Giannatempo Simone Rota Valentina Tateo